Sanofi

Aventis Pharmaceuticals Inc.

Aventis Pharma Limited

Stephanie Deprets

Jean-Christophe Carry

Olivier Duclos

Sergio Mallart

Tahir Nadeem Majid

Maria Mendez-Perez

Vincent Leroy

Paul Joseph Cox

Shelley Amendola

Fabienne Chatreaux

Fabrice Vergne

Andrew David Morley

Christopher D Edlin

Dominique Melon-Manguer

Michael L Edwards

Brian L Pedgrift

Herve Bouchard

Charles J Gardner

Timothy A Gillespy

Frank Halley

Didier Babin

John Charles Reader

Michael Cherry

Laurence Gauzy

Nawaz Mohammed Khan

Justine Yeun Quai Lai

Alain Le-Brun

Lloyd J Payne

Dominique Damour

Conception Nemecek

Francois Clerc

David John Aldous

Iain M McLay

Bernard Baudoin

Chantal Carrez

Dorothea Kominos

Olivier Houille

Daniel N A Bezard

Christoper David Edlin

Justine Y Q Lai

The present invention relates to compounds of formula (1): wherein R6 is &#x2014;CONHor a &#x2014;C(R)(R)(OH) group; R is a substituted phenyl or heteroaryl group; R7 is an optionally substituted aryl or heteroaryl group. Process for the preparation thereof and therapeutic use thereof.

Thienopyrimidine derivatives, processes for the preparation thereof and therapeutic uses thereof

The present invention relates to compounds of formula (I): wherein R6 is &#x2014;CONHor a &#x2014;C(R)(R)(OH) group; R is a substituted phenyl or heteroaryl group; R7 is an optionally substituted aryl or heteroaryl group. Process for the preparation thereof and therapeutic use thereof.

The present invention relates to therapeutic uses of the compounds of formula (I): wherein R6 is &#x2014;CONHor a &#x2014;C(R)(R)(OH) group; R is a substituted phenyl or heteroaryl group; R7 is an optionally substituted aryl or heteroaryl group.

Therapeutic uses of novel thienopyrimidine derivatives

The invention is directed to physiologically active compounds of the general formula (Ix) and compositions containing such compounds, and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (Ix), and to processes for their preparation. Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit kinases.

Benzimidazoles

The invention is directed to physiologically active compounds of general formula (I):&#x2014; and compositions containing such compounds; and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (I). Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit kinases.

Azaindoles for inhibiting aurora2 and other kinases

Compounds of the formula and N-oxides, prodrugs, acid bioisosteres, pharmaceutically acceptable salts or solvates of such compounds, or N-oxides, prodrugs, or acid bioisosteres of such salts or solvates, to compositions comprising such compounds, and methods of treatment comprising administering, to a patient in need thereof, such compounds and compositions.

Pyrrolopyrimidines

Chemical compositions containing physiologically active compounds of general formula (I): wherein Ris aryl or heteroaryl; Rrepresents hydrogen, acyl, cyano, halo, lower alkenyl or lower alkyl optionally substituted by a substituent selected from cyano, heteroaryl, heterocycloalkyl, -ZR, &#x2014;C(&#x2550;O)&#x2014;NYY, &#x2014;COR, &#x2014;NYY, &#x2014;N(R)&#x2014;C(&#x2550;O)&#x2014;R, &#x2014;N(R)&#x2014;C(&#x2550;O)&#x2014;NYY, &#x2014;N(R)&#x2014;C(&#x2550;O)&#x2014;OR, &#x2014;N(R)&#x2014;SO&#x2014;R, &#x2014;N(R)&#x2014;SO&#x2014;NYYand one or more halogen atoms; Rrepresents hydrogen, aryl, cyano, halo, heteroaryl, lower alkyl, &#x2014;C(&#x2550;O)&#x2014;ORor &#x2014;C(&#x2550;O)&#x2014;NYY; and Xrepresents N, CH, C-halo, C&#x2014;CN, C&#x2014;R, C&#x2014;NYY, C&#x2014;OH, C-ZR, C&#x2014;C(&#x2550;O)&#x2014;OR, C&#x2014;C(&#x2550;O)&#x2014;NYY, C&#x2014;N(R)&#x2014;C(&#x2550;O)&#x2014;R, C&#x2014;SO&#x2014;NYY, C&#x2014;N(R)&#x2014;SO&#x2014;R, C-alkenyl, C-alkynyl or C&#x2014;NO; and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (I). Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit protein kinases.

Azaindoles

The invention is directed to physiologically active compounds of the general formula (Ix)and compositions containing such compounds, and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (Ix), and to processes for their preparation. Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit kinases.

Growing community of inventors

Paris, France

Stephanie Deprets